Athira Pharma ATHA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Athira Pharma (ATHA)
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.3415Market Cap
$13.33 MillionPrice-Earnings Ratio
-0.12Total Outstanding Shares
39.04 Million SharesTotal Employees
26Dividend
No dividendIPO Date
September 18, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockHeadquarters
18706 north creek parkway, suite 104, Bothell, WA, 98011Homepage
https://www.athira.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $312,000 |
| Net Cash Flow, Continuing | $-90.95 Million |
| Net Cash Flow From Financing Activities | $312,000 |
| Net Cash Flow From Investing Activities, Continuing | $64.03 Million |
| Net Cash Flow | $-90.95 Million |
| Net Cash Flow From Investing Activities | $64.03 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $38.43 Million |
| Operating Income/Loss | $-114.35 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income/Loss From Continuing Operations After Tax | $-109.22 Million |
| Diluted Average Shares | $38.43 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-28.37 Million |
| Comprehensive Income/Loss Attributable To Parent | $-108.54 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-108.85 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $22.92 Million |
| Fixed Assets | $2.69 Million |
| Current Liabilities | $27.75 Million |
| Wages | $4.44 Million |
| Liabilities And Equity | $86.25 Million |
| Current Assets | $82.00 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ATHA from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.